{Reference Type}: Journal Article
{Title}: A single dose of angiotensin-(1-7) resolves eosinophilic inflammation and protects the lungs from a secondary inflammatory challenge.
{Author}: Magalhaes GS;Gregorio JF;Beltrami VA;Felix FB;Oliveira-Campos L;Bonilha CS;Righetti RF;Tibério IFLC;De Sousa FB;Rezende BM;Teixeira-Carvalho A;Santos RA;Campagnole-Santos MJ;Rodrigues-Machado MDG;Teixeira MM;Pinho V;
{Journal}: Inflamm Res
{Volume}: 73
{Issue}: 6
{Year}: 2024 Jun 24
{Factor}: 6.986
{DOI}: 10.1007/s00011-024-01880-x
{Abstract}: <B>OBJECTIVE: </B>Angiotensin-(1-7) [Ang-(1-7)] is a pro-resolving mediator. It is not known whether the pro-resolving effects of Ang-(1-7) are sustained and protect the lung from a subsequent inflammatory challenge. This study sought to investigate the impact of treatment in face of a second allergic or lipopolysaccharide (LPS) challenge.<BR><B>METHODS: </B>Mice, sensitized and challenged with ovalbumin (OVA), received a single Ang-(1-7) dose at the peak of eosinophilic inflammation, 24 h after the final OVA challenge. Subsequently, mice were euthanized at 48, 72, 96, and 120 h following the OVA challenge, and cellular infiltrate, inflammatory mediators, lung histopathology, and macrophage-mediated efferocytic activity were evaluated. The secondary inflammatory stimulus (OVA or LPS) was administered 120 h after the last OVA challenge, and subsequent inflammatory analyses were performed.<BR><B>RESULTS: </B>Treatment with Ang-(1-7) resulted in elevated levels of IL-10, CD4+Foxp3+, Mres in the lungs and enhanced macrophage-mediated efferocytic capacity. Moreover, in allergic mice treated with Ang-(1-7) and then subjected to a secondary OVA challenge, inflammation was also reduced. Similarly, in mice exposed to LPS, Ang-(1-7) effectively prevented the lung inflammation.<BR><B>CONCLUSIONS: </B>A single dose of Ang-(1-7) resolves lung inflammation and protect the lung from a subsequent inflammatory challenge highlighting its potential therapeutic for individuals with asthma.